1 800 GET THIN Comes to San Francisco and San Jose Areas AVITAL WEB INC. Posted on:29 Nov 11 PR Newswire SAN FRANCISCO, Nov. 29, 2011 SAN FRANCISCO, Nov. 29, 2011 /PRNewswire/ — 1 800 GET THIN has helped thousands of people take their first steps towards leading a healthier life, and it is now accepting calls from those who live in the San Francisco and San Jose . The FDA has approved the LAP BAND System for use in people whose body mass index, or BMI, is at least 30 and who have one or more obesity-related health conditions. You can more easily determine your BMI with 1800getthin.com’s simple and helpful BMI calculator. First used in Europe, the LAP BAND System was approved for use in the United States in 2001. According to a new study that was reported by CBS News, as many as 25 percent of all Californians are obese. One of those helped by the procedure is Sara Fincher. Sara is a successful real estate agent, but she was far less successful when it came to losing weight. Sara weighed 200 pounds at just 5 feet 3 inches tall. She had tried many different diet and exercise programs throughout her life, but not matter what she did, she just couldn’t lose the weight. Two years ago, however, she had the LAP BAND procedure. Since then, she has lost 75 pounds, and she looks and feels great. She can fit into sizes two and four clothes, and her coworkers are inspired by her success. The LAP BAND System may be able to help those who have tried traditional diet and exercise or other weight loss programs but who have been unable to lose weight or those who have lost weight and regained it. The LAP BAND System has helped hundreds of thousands of people all over the world lose weight when other weight loss methods like diet and exercise have failed. According to studies, people may be able to lose between 30 and 50 percent of their excess weight within three years of their LAP BAND procedure. To learn more about losing weight, making positive lifestyle changes or the LAP BAND procedure, call 1 800 GET THIN or visit 1800getthin.com today. 1 800 GET THIN is not a medical service provider or doctors’ office, and it does not operate medical facilities. All surgical procedures carry risks. Before beginning any weight loss program, individuals should talk to a health care professional. 1 800 GET THIN is a marketing company which connects individuals with medical facilities and doctors who specialize in handling the medical needs of obese individuals in locations throughout Southern California such as Apple Valley, Beverly Hills, Bakersfield, Long Beach, Palmdale, Pomona, San Bernardino, San Diego, Santa Ana, Valencia and West Hills, and locations in Northern California such as Fremont, San Jose and San Francisco. PR by http://www.seocompanyca.com SOURCE 1 800 GET THIN PR Newswire http://www.prnewswire.co.uk/ Last updated on: 29/11/2011 15:00:14

A team of researchers at Case Western Reserve University School of Medicine has developed the first “theranostic” agent for the treatment of acute lymphoblastic leukemia (ALL). ALL is the most common type of childhood cancer diagnosed in approximately 5,000 new cases each year in the United States. The findings provide insight into pediatric oncology that specifically focuses on the development of “theranostic” agents – a treatment platform that combines a selective diagnostic test with targeted therapy based on the test results. Discovery of this new class of drugs is the first step towards new diagnostic markers and therapeutic approaches in treatments with anti-cancer agents of numerous other cancers in addition to ALL. “This discovery takes a chemical biology approach to target ALL. Our nucleosides represent a new class of theranostic agents that provide an original approach to achieving personalized treatments against pediatric leukemia,” says Anthony J. Berdis, PhD, assistant professor of pharmacology at Case Western Reserve School of Medicine. “We’ve developed a non-natural nucleoside that specifically targets this form of childhood leukemia. The combination of therapeutic and diagnostic activities will provide more selective and more expedient ways to treat patients by optimizing the dosages needed to kill the cancer cells without affecting normal cells. This selectivity should minimize the development of adverse side effects typically associated with conventional anti-cancer nucleosides,” says Dr. Berdis. Using an enzyme implicated in the disease, terminal deoxynucleotidyl transferase (TdT) which serves as a biomarker and is overexpressed in 90 percent of ALL patients, Dr. Berdis and his team designed a new selective anti-cancer agent against ALL. By evaluating the anti-leukemia activities of two non-natural nucleotides designated 5-NITP and 3-Eth-5-NITP, the investigators strategically placed novel functional groups on these agents so that they could be tagged with fluorogenic dyes. These taggable nucleotides improve the accuracy of dosing regiments and could accelerate clinical decisions regarding therapeutic intervention. The next steps will be validation in animal studies and toxicology testing, leading to clinical trials. This study appears online this week in ACS Chemical Biology. In addition to Dr. Berdis, co-authors on the paper include Edward A. Motea and Dr. Irene Lee, in the Department of Chemistry and Department of Pharmacology at Case Western Reserve. Acute lymphoblastic leukemia (ALL) is a form of leukemia, or cancer of the white blood cells characterized by excess lymphoblasts. Acute refers to the relatively short time course of the disease (being fatal in as little as a few weeks if left untreated). This disease is caused when malignant, immature white blood cells continuously multiply and are overproduced in the bone marrow. ALL causes damage and death by crowding out normal cells in the bone marrow and by spreading to other organs. Although ALL is most common in childhood with a peak incidence at 2-5 years of age, this type of leukemia is also prevalent in people over the age of 60. Funding for this research was provided by the NIH and the National Cancer Institute Training Programs in Cancer Pharmacology. This research was supported by the Developmental Therapautics Program at the Case Comprehensive Cancer Center, a National Cancer Institute (NCI) – designated Comprehensive Cancer Center located at Case Western Reserve University in Cleveland, Ohio. NCI-designated cancer centers are characterized by scientific excellence and the capability to integrate a diversity of research approaches to focus on the problem of cancer. Lead by Stanton Gerson, MD, Asa and Patricia Shiverick- Jane Shiverick (Tripp) Professor of Hematological Oncology, director of the Case Comprehensive Cancer Center, and director of the Seidman Cancer Center at UH Case Medical Center. The Case Comprehensive Cancer Center, now in its 22nd year of funding, integrates the cancer research activities of the largest biomedical research and health care institutions in Ohio – Case Western Reserve University, University Hospitals Case Medical Center, Cleveland Clinic and MetroHealth Medical Center. About Case Western Reserve University School of Medicine Founded in 1843, Case Western Reserve University School of Medicine is the largest medical research institution in Ohio and is among the nation’s top medical schools for research funding from the National Institutes of Health. The School of Medicine is recognized throughout the international medical community for outstanding achievements in teaching. The School’s innovative and pioneering Western Reserve2 curriculum interweaves four themes – research and scholarship, clinical mastery, leadership, and civic professionalism – to prepare students for the practice of evidence-based medicine in the rapidly changing health care environment of the 21st century. Nine Nobel Laureates have been affiliated with the school of medicine. Annually, the School of Medicine trains more than 800 MD and MD/PhD students and ranks in the top 25 among U.S. research-oriented medical schools as designated by U.S. News & World Report “Guide to Graduate Education.” The School of Medicine’s primary affiliate is University Hospitals Case Medical Center and is additionally affiliated with MetroHealth Medical Center, the Louis Stokes Cleveland Department of Veterans Affairs Medical Center, and the Cleveland Clinic, with which it established the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in 2002. Researchers develop first 'theranostic' treatment for acute lymphoblastic leukemia (ALL)

Health economics is one of those rapidly growing fields that links up business with health care. A health economist has a unique passion for using their knowledge of economics by applying it to a variety of challenges in health and medicine. As the population continues to grow, the demand for quality and cost-effective health care similarly grows, leaving careers in health economics vital to sustaining our health care system. Health economists are professionals who i... What does a Health Economist Do?

BioClinica®, Inc. (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced that Onconova Therapeutics®, Inc. has extended agreements using BioClinica Express electronic data capture (EDC) and data management services to support their clinical trials world-wide. Onconova has a number of clinical-stage products and a growing number of pre-clinical candidates. These development stage compounds are novel small molecules for the treatment of a broad range of hematologic malignancies and solid tumors. “We collaborate with a number of Clinical Research Organizations,” said Dennis C. Earle, Vice President of Clinical Operations at Onconova, “so using BioClinica Express for our trials has helped us to standardize processes. BioClinica has been flexible and responsive, implementing a collaborative, real-time UAT (user acceptance testing) process to help Onconova meet study launch timelines. BioClinica’s Forms and Study Design Team, in conjunction with the Data Management team, have worked together to ensure optimal use of the technology while re-using established eCRFs (electronic case report forms) in order to support rapid study builds.” Onconova has benefited from a number of eCRFs and tools developed by BioClinica specifically to support oncology trials. BioClinica Express EDC offers standard RECIST (Response Evaluation Criteria In Solid Tumors) eCRFs that automatically calculate overall tumor response based on the data entered. A dynamic lesion form uses derived data to help sites consistently track lesions from visit to visit. BioClinica’s preconfigured library of oncology forms also includes functionality that guides sites through adding adverse events in a way that eliminates the coding step required when entering verbatim terms, and allows the site to fully understand the National Cancer Institute CTCAE (Common Terminology Criteria for Adverse Events) grades available for each particular event. BioClinica also worked with Onconova to develop a custom study drug re-supply algorithm to support its unique study design, implemented a daily lab import feed to minimize data entry and a local lab range import to streamline reconciliation. “The approach being employed by Onconova represents some of the most innovative cancer research in the country, and we are proud to support those efforts,” said Peter Benton, President of eClinical Solutions for BioClinica. “The selection of BioClinica by Onconova reaffirms our cutting-edge and user-friendly technology. It also demonstrates BioClinica’s ability to deliver effective clinical research solutions for sponsors and Clinical Research Organizations of any size, and for all clinical trial phases and therapeutic categories.” Follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog , and on twitter at http://twitter.com/bioclinica . About Onconova Therapeutics ® , Inc. Onconova, based in Newtown, PA and Pennington, NJ, and founded in 1998, discovers and develops novel small molecule therapeutics targeting signal transduction, cell-cycle, and DNA repair pathways. Onconova has a novel discovery platform focusing on non-ATP competitive kinase inhibitors. These products, technologies, and candidates are derived internally from a proprietary library of new chemical entities. In addition to rigosertib and other anti-cancer drug candidates, Onconova is also developing Ex-RAD® (ON 01210.Na) as a novel radiation protectant (oral and injection) against radiation injury of tissue and whole body. For additional information, please visit http://www.onconova.com . About BioClinica, Inc. BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com . Certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995.In particular, the Company’s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company’s financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company’s control.The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements.The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company’s filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q. Business Wire http://www.businesswire.com/ Last updated on: 30/11/2011 12:00:06

There has been fierce criticism of nursing care of the elderly in hospital, with patients reported to have been drinking from flower vases because they were so thirsty, and meals regularly being left out of reach.   Photo: MARTIN POPE While not recorded as the cause of death, the \"effects of hunger\" were noted on the death certificates of 301 people in England in 2010, u... Growing number of hospital patients are malnourished when they die

PBR Staff Writer Published 22 December 2011 Dynavax Technologies initiates a proof-of-mechanism clinical trial of the TLR7 and TLR9 inhibitor, DV1179, in systemic lupus erythematosus (SLE) patients. Initiation of the trial entitles Dynavax to obtain a m milestone payment from GlaxoSmithKline (GSK) under their worldwide strategic alliance. GSK has an exclusive option to obtain a license to the program following completion of this trial. The first of two stages of the trial will evaluate ascending doses of DV1179 for safety and tolerability i... Dynavax initiates proof-of-mechanism trial for SLE patients

Invalid URL supplied

Lead exposure is preventable. Find out about common sources of lead exposure and what you can do to protect your child. By Mayo Clinic staff Young children are at the greatest risk of health problems related to lead exposure, including serious brain and kidney damage. Children age 3 and under are especially vulnerable because their ways of playing and exploring — such as crawling and putting objects in their mouths — increase their risk of contact with lead, and of lead entering their bodies through breathing or swallowing. What are the commo... Lead exposure: Tips to protect your child

WOUND MANAGEMENT TECHNOLOGIES, INC. (WNDM) Stock Message Board Invalid URL supplied

PBR Staff Writer Published 16 December 2011 Enlight Biosciences, an entrepreneurial partnership with pharmaceutical businesses, has entered partnerships with AstraZeneca and Novo Nordisk to help the businesses in the development of their therapeutic programs. Enlight emphasizes on locations including molecular imaging, biologics, drug formulation delivery methods, besides novel chemistries, production technologies, biomarkers and drug safety. Enlight CEO Michelle Browner said the company hopes to benefit from contributions of AstraZeneca and Novo Nordisk. AstraZeneca Innovative Medicines Executive Vice President Menelas Pangalos said Enlight would give an chance for its biologics arm, MedImmune, to support the development of tools that will boost R&D across the industry. Enlight joins AstraZeneca, Novo Nordisk for therapeutics development